Compound 19A8.8
Compound 19A8.8 is a cyclic peptide derived from a CD36 protein fragment. Compound 19A8.8 inhibits the TGF-β/Smad3 signaling pathway by suppressing the interaction between TSP1 and CD36. Compound 19A8.8 has no obvious cytotoxicity. Compound 19A8.8 can be used for research on colon injury and fibrosis[1].
Product Specifications
UNSPSC
12352209
Target
TGF-beta/Smad; TGF-β Receptor
Related Pathways
Stem Cell/Wnt; TGF-beta/Smad
Field of Research
Neurological Disease
Smiles
O=C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C(C)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCC(N)=O)C(N[C@H]1CC(O)=O)=O)=O)=O)=O)=O)[C@H](CCCCN)NC1=O
Molecular Formula
C35H60N12O13
Molecular Weight
856.92
References & Citations
[1]Zhang W, et al. Design and discovery of novel cyclic peptides as TSP1-CD36 interaction inhibitors for intestinal fibrosis treatment. Bioorg Chem. 2025 Aug;163:108667.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400669-500 1x 500 µL
P27 / KIP1 (SX53G8), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680178-500 1x 500 µL
CD50 (ICAM-3) (186-2G9), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details